| Literature DB >> 28688748 |
Maria Sframeli1, Anna Sarkozy2, Marta Bertoli3, Guja Astrea4, Judith Hudson3, Mariacristina Scoto2, Rachael Mein5, Michael Yau5, Rahul Phadke2, Lucy Feng2, Caroline Sewry2, Adeline Ngoh Seow Fen2, Cheryl Longman6, Gary McCullagh7, Volker Straub3, Stephanie Robb2, Adnan Manzur2, Kate Bushby3, Francesco Muntoni8.
Abstract
Congenital muscular dystrophies (CMDs) are clinically and genetically heterogeneous conditions; some fatal in the first few years of life and with central nervous system involvement, whereas others present a milder course. We provide a comprehensive report of the relative frequency and clinical and genetic spectrum of CMD in the UK. Genetic analysis of CMD genes in the UK is centralised in London and Newcastle. Between 2001 and 2013, a genetically confirmed diagnosis of CMD was obtained for 249 unrelated individuals referred to these services. The most common CMD subtype was laminin-α2 related CMD (also known as MDC1A, 37.4%), followed by dystroglycanopathies (26.5%), Ullrich-CMD (15.7%), SEPN1 (11.65%) and LMNA (8.8%) gene related CMDs. The most common dystroglycanopathy phenotype was muscle-eye-brain-like disease. Fifteen patients carried mutations in the recently discovered ISPD, GMPPB and B3GALNT2 genes. Pathogenic allelic mutations in one of the CMD genes were also found in 169 unrelated patients with milder phenotypes, such as limb girdle muscular dystrophy and Bethlem myopathy. In all, we identified 362 mutations, 160 of which were novel. Our results provide one of the most comprehensive reports on genetics and clinical features of CMD subtypes and should help diagnosis and counselling of families with this group of conditions.Entities:
Keywords: B3GALTN2; COL6A1-A2-A3; Congenital muscular dystrophy; Dystroglycanopathies; GMPPB; ISPD; LAMA2; LMNA; Prevalence; SEPN1
Mesh:
Substances:
Year: 2017 PMID: 28688748 DOI: 10.1016/j.nmd.2017.06.008
Source DB: PubMed Journal: Neuromuscul Disord ISSN: 0960-8966 Impact factor: 4.296